Stifel Nicolaus analyst Derek Archila initiated coverage with a Hold rating on Amarin today and set a price target of $5.00. The company’s shares closed last Thursday at $4.67, close to its 52-week low of $3.36.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 10.7% and a 49.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amarin with a $10.70 average price target.
Selecta Biosciences (SELB)
In a report released today, Raju Prasad from William Blair downgraded Selecta Biosciences to Hold. The company’s shares closed last Thursday at $3.09.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 14.1% and a 56.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Selecta Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.